Investing With IBD cover image

Ep 182: Simon Erickson: EV Stocks Powering Up?

Investing With IBD

CHAPTER

CME: Arusha's Growth Strategy

It's right up there on kind of the when you look at the screening from an O'Neill perspective EPS rating of 92. So outperforming 92% of the stocks in our database and RS rating of 93. It is setting up it broke out of a consolidation. You can see now the focus on where the money is at, right? Gross margin just within the past year alone grew from 32% to 38%.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner